Professional Documents
Culture Documents
The Problem
Pets are living longer than ever before, making them
more susceptible to developing cancer
Cancer is the # 1 disease related cause of death
for dogs in the U.S.
Cancer accounts for almost 50% of deaths in pets
older than 10 years
Average costs to treat lymphoma in pets is
$2,000-most owners will rather watch their pets
die than pursue treatment
1 in 4 dogs and 1 in 5 cats will develop cancer in
their lifetime
Dogs get cancer at about the same rate as
humans
Current Solutions
The most common treatment modalities used to combat cancer include: Surgical treatment, Chemotherapy,
Radiation Therapy and Immunotherapy.
PALLADIA is the first and only FDA-approved drug for canine cancer. While it is administered orally, it
is still technically chemotherapy. Side effects may include low white blood cell counts, diarrhea,
vomiting, lethargy, fatigue, and stomach ulceration.
Low response rate, roughly 40% of dog with mast cell tumors will actually respond to the drug, while
the majority do not.
(US National Library of Medicine National Institutes of Health)
Market Opportunity
In 2015, $60.28 billion was spent
on pets in the U.S.-26% on vet
care services
Food
23.05
Supplies/OTC
Medicine
14.28
Vet Care
15.42
Live
animal purchases
Pet2.12
Services: grooming & boarding
5.41
Breakdown: Spending on
Pets in 2015 ($ billions)
Market Opportunity
Current treatment methods are quite expensive and
not totally safe for pets
Initial visit, including diagnosis, discussion of
prognosis and a treatment plan
$200+
Major surgery to remove a tumour deep in the
body, or that requires reconstruction
$1500+
Chemotherapy (depends on the size of the
dog)
ranges from $200 to $2,000 and up
Radiation therapy
ranges from $2,000 to $6,000
Pain medications
$25 to $50 a
month.
CASE REPORT
I
Amount spent: $3,000
Posted by : Irena in Vancouver. CA,
Breed : Shepxgolden
Treatment : Owner Took no action/did
not seek further
treatment
Posted
: March 3rd, 2011
08:03 PM
Cancer Type : Intestinal
NEYMAR BLACK
Entertainment
10
11
Escozine
for
Pets
Escozine for Pets has a number
of
advantages over current treatment
12
13
Testimonials
14
Testimonials
15
Revenue Model
16
anonymous
Expanding into new geographical markets. Each year, the company will open a new
distribution center in a strategic geographical market i.e. India, Latin America and others
Ease of availability, cost effectiveness, easy administering, and aggressive brand building
activities, will drive sales increases at a fast pace, year on year
17
Competition
Competitor
18
Description
Company/Drug
Conditionally approved by FDA in 2010, Kinavet-CA1, is a tyrosine kinase inhibitor. It is used to
treat mast cell tumors, a common form of cancer that affects dogs. Kinavet-CA1 works in three
ways: by blocking the survival signal of the tumor cells, which may induce disappearance of the
tumor, by preventing tumor growth and preventing the spread of tumor cells (metastasis).
Paccal VetCA1 has been granted conditional approval by the FDA for the treatment of: nonresectable stage III, IV or V mammary carcinoma in dogs that have not received previous
chemotherapy, or radiotherapy and resectable and non-resectable squamous cell carcinoma in
dogs that have not received previous chemotherapy, or radiotherapy.
The only drug fully approved by the FDA for the treatment of cancer in canines is Palladia.
Palladia is a prescription-only therapy is used to treat grade II or III recurrent cutaneous mast
cell tumors with or without regional lymph node involvement. It works by blocking the activity of
key receptors important in the development of blood vessels that supply tumors, as well as
receptors vital for tumor survival.
19
Competitive Advantage
Esozine for Pets
of areas:
20
Positioning
We will position Escozine for Pets in
the market as a non-invasive, cost
effective ($249 cost of treatment per
patient for each month) drug in the
pet oncology market
Escozine
Surgery
Chemotherapy
Radiation
Therapy
21
22
Financial Projections
23
High product margins, and fast revenue growth across all product categories (more than 100% sales growth in
the first three years) will see the company in a healthy cash positition
Investment Proposal
24
Petlife Pharma is seeking to raise $8.5 million through a private placement offering to fund
the approval and launch of Escozine for Pets. The initial part of our raise is $400,000.
25
Investment Proposal
In return for $8.5 million, the company shall issue 17,000,000 shares to investors, which are
equal to a 22.5% stake in the company after dilution.
Common
Shares
Commo
n
Options
Phase
One
$
Invested
Phase
One
Shares
Phase
One
%
Fully Diluted
Shares
% Fully
Diluted
Shareholder
Irrevocable de
Fidecomison Confianza
General De Familiar
Irrevocable
30,700,00
0
$0
0.0% 30,700,000
5,700,000
$0
0.0% 5,700,000
Shareholders with
under 5%
11,083,65
2
$0
0.0% 11,083,652
14.6%
Elite International
Partners, Inc.
11,203,12
5
$0
0.0% 11,203,125
14.8%
100.0% 17,000,000
22.5%
17,000,00
$8,500,000 0
40.6%
7.5%
26
Investment Proposal
Value per Share ($) and Market Cap ($ million)
27
Key Milestones
Sources
DRESSLER, D. (2009). Palladia, First Dog Cancer Drug FDA Approved But Not Great. Retrieved May 29,
2016, from
http://www.dogcancerblog.com/blog/first-dog-cancer-drug-fda-approved-but-not-great/
The Ins and Outs of Cancer in Pets. (2016). Retrieved May 29, 2016, from
http://www.vosrc.net/blog/the-ins-and-outs-of-cancer-in-pets/
How Much Does Dog Cancer Treatment Cost? - CostHelper.com. (n.d.). Retrieved May 29, 2016, from
http://pets.costhelper.com/dog-cancer-treatment.html
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate
(SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or
distant) mast cell tumor following surgical excision. (2009, June/July). Retrieved May 29, 2016, from
http://www.ncbi.nlm.nih.gov/pubmed/19470739
Pet Cancer Facts and Figures. (n.d.). Retrieved May 29, 2016, from
http://www.petinsurance.com/healthzone/pet-articles/pet-infographics/Pet-Cancer-Facts-and-Figures-In
fographic.aspx
Pet Industry Market Size & Ownership Statistics. (n.d.). Retrieved May 29, 2016, from
http://www.americanpetproducts.org/press_industrytrends.asp
Rusk, A., Dr. (n.d.). Cancer is the leading cause of death in dogs and cats. Retrieved May 29, 2016, from
http://www.vetcontact.com/en/art.php?a=773
28